Tag Archives: HEA

PR Newswire

Mediballoon’s Online Shop is now live, offering a range of medical balloons and tubing for sale. Mediballoon is your best partner for medical device development.

Leave a comment

UNION CITY, Calif., Aug. 9, 2023 /PRNewswire/ — Mediballoon, Inc., a Medeologix company established in 2016 specializing in medical balloon design, development, and scale-up production, is excited to announce the launch of the Mediballoon Online Shop. This newly unveiled platform caters to engineers, designers, and innovators seeking to rapidly prove their concepts in advanced medical devices, by offering a wide array of balloons and tubing products.

Balloon development center of Mediballoon
Balloon development center of Mediballoon

Mediballoon’s online shop features a user-friendly interface that simplifies the process for customers to quickly select diverse processes, materials, shapes, and sizes, all accessible within an expedited timeframe to complete purchases, effectively eliminating uncertainties during development and enhancing the shopping journey. “We understand the eagerness to promptly prove the concept, especially in today’s rapidly evolving environment where time is crucial,” stated Anant Hegde, the founder, and CEO of Mediballoon, Inc. Mediballoon’s online shop ensures rapid shipment within 48 hours, meeting the demands of today’s fast-paced world.

With 25 years of experience, Mediballoon excels in the field of balloon and tubing development. This expertise spans balloon tubing, single lumen catheter tubing, multi-lumen tubing with up to 8 lumens, and heat shrink tubing. Mediballoon’s expertise is now complemented by its comprehensive one-stop-shop service, effectively alleviating numerous challenges engineers encounter. This service includes rapid prototyping, engineering assistance, pilot production, and scale-up production, all aimed at providing straightforward solutions that swiftly transform innovative ideas into tangible medical advancements.

Mediballoon also offers a seamless transition from pilot production to a mass production site in Taiwan. With engineering excellence, sourcing, and supply chain integration, the Taiwan mass production facility enhances cost-effectiveness, improves efficiency, and enables faster responses to market demands. “Whether you need support for quick component development or moving towards mass production, Mediballoon is your best partner in balloon manufacturing and extrusion,” said Hegde.

For more information, please visit:
Mediballoon Online Shop: www.medeologix.com/online-shop
Mediballoon Website: www.medeologix.com/mediballoon

About Mediballoon, Inc.

Mediballoon is an expert in extruding medical tubing and developing medical balloons in different shapes and sizes using various thermoplastic materials including Polyurethane, Polyethylene, Polyvinylidene fluoride (PVDF), Polybutylene terephthalate (PBT), Polyethylene terephthalate (PET), PEBAX, and Nylons.

Mediballoon has received ISO 13485:2016 certification, underscoring their dedication to delivering safe and effective medical solutions for the ultimate benefit of patients.

PR Newswire

TraceLink Accelerates DSCSA 2023 Customer Readiness, Supply Chain Digitalization, and Drug Shortage Predictability in Second Quarter of 2023

Leave a comment

As the industry prepares for DSCSA 2023 regulations, 50% of the US MAH market is now EPCIS-enabled through the TraceLink B2N Integrate-Once network. This digital foundation is allowing them to enhance supply chain visibility, collaboration, and resilience.

BOSTON, July 28, 2023 /PRNewswire/ — TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 290,000 healthcare and life sciences entities through its B2N Integrate-Once™ network, today announced significant business growth and rapidly accelerating network adoption. With the looming Drug Supply Chain Security Act (DSCSA) compliance deadline on November 27, 2023, pharmaceutical supply chain companies continue to expand digital network connections on the TraceLink network to improve supply chain performance and leverage the extensive serialization and track-and-trace network foundation to tackle the ongoing challenges of drug shortages.

Key highlights of the quarter include:

  • 43 new customer accounts and 90 new customer projects initiated for DSCSA compliance.
  • 3,115 network links created across 504 companies on the TraceLink network.
  • Protected 100,000 patients from drug shortages and saved pharmacies millions of dollars in revenue by predicting shortages in advance with Product Availability Intelligence solution.
  • Surpassed one billion DSCSA Transaction Histories processed on the TraceLink network.
  • Surpassed one million DSCSA-compliance EPCIS transactions exchanged between trading partners on the TraceLink network.
  • Launched the Multienterprise Information Network Tower (MINT) solution to power end-to-end, real-time supply chain visibility and multienterprise process collaboration.
  • Launched Supply Chain Work Management for Compliance Exceptions to provide an automated and efficient solution to manage and reconcile DSCSA and other compliance exceptions between trade partners.
  • Hosted more than 200 healthcare and life sciences industry professionals from over 75 companies at 30+ sessions at FutureLink 2023. The TraceLink conference focused on DSCSA 2023 readiness plans, emerging opportunities to address drug shortages by leveraging AI with supply chain data, and building a foundation for supply chain digitalization to drive better end-to-end visibility, collaboration, and intelligence.

Speaking about why Sentara Health chose TraceLink as their DSCSA compliance partner, Tyler Martinson, Pharmacy Manager at Sentara Health, had this to say: “TraceLink was vital to this role, their support, both their IT and just their knowledge of the law. Laws change and rules keep coming out and it was very helpful to have someone who was really focused on that to help explain to us what was coming down the road and what we should be aiming towards.”

TraceLink continues its 10+ year investment in helping companies across the pharmaceutical and healthcare supply chain—from pharmaceutical manufacturer to healthcare provider and retail pharmacy—meet the complex unit-level traceability, verification, and other requirements of track-and-trace regulations like DSCSA while helping those companies improve the predictability, agility, and performance of their supply chain operations. Leveraging the interoperable TraceLink network spanning over 120 countries and over 290,000 authenticated pharmaceutical manufacturers, distributors, retail pharmacies, and healthcare providers, TraceLink has enabled over 15,000 live serialization connections, manages over 41 billion serialized products on its network, processes over 50K ASNs a month, and has saved the pharmaceutical industry more than $4.7B in unnecessary point-to-point integration costs by exchanging critical business transactions on the TraceLink network.

To talk with TraceLink experts about our unique approach to helping companies across the pharmaceutical and healthcare supply chain ensure global compliance with track-and-trace regulations while laying the foundation for end-to-end product orchestration and unsurpassed supply chain performance, please visit tracelink.com.

About TraceLink
TraceLink is the pharmaceutical and life sciences industry’s leading provider of supply chain digitalization through end-to-end product orchestration on the Opus digital network platform. With more than 290,000 network members, Opus connects people, processes, systems, and enterprises into a collective information network for intelligent business execution. TraceLink serialization, global track-and-trace compliance, end-to-end supply chain visibility, and real-time supply chain collaboration solutions empower customers to achieve massive scalability, maintain continuous compliance, and ensure supply through a single connection to our B2N Integrate-Once™ network. TraceLink customers serialize more than one billion units per month across 15,000 connections and process over 50K ASNs a month over our network.

Source: TraceLink, Inc.

PR Newswire

Project Matty: Revolutionizing Care for Children with Autism and ADHD Through AI

Leave a comment

SINGAPORE, July 24, 2023 /PRNewswire/ — Project Matty, a pioneering digital health solution, has been launched by a dedicated mother of an ADHD-diagnosed child and Dr. Pamela Lim, a clinical psychology doctor. Both inspired by their personal experiences and united by their commitment to improve the lives of children with autism and ADHD, they’re harnessing the power of artificial intelligence (AI) for an extraordinary mission.

The co-founders’ personal journeys fuel their resolve to bridge the gap in traditional treatments. Born out of one mother’s determination to help her ADHD-diagnosed son, and Dr. Pamela Lim’s drive to assist others like her own child with autism, Project Matty aims to provide more accessible, effective, and personalized care to children worldwide.

Enter M.A.T.T.Y – an acronym for Managing Autism/ADHD Through Texting to You. It’s an AI system that leverages the simplicity and familiarity of texting. M.A.T.T.Y engages in insightful chats with caregivers, learning about each child’s unique traits, and using this information to create personalized virtual pets. These AI-powered pals provide children with an engaging, safe environment where they can develop essential skills beyond clinical settings.

Dr. Pamela Lim, a stalwart in the field of clinical psychology, emphasizes the core philosophy of Project Matty. “Kids with neurodevelopmental disorders behave differently because their brains process the world differently. They’re not abnormal, just different. By understanding how they perceive the world, we can help them integrate into what may seem a frightening and strange world. Our mission with M.A.T.T.Y is to empower caregivers, who can then empower these amazing kids.”

Project Matty embodies the transformative potential of technology when combined with deep empathy and personal experience. It presents a significant opportunity for investors looking to support an innovative solution with vast societal impact.

Join Project Matty in empowering children with Autism and ADHD to reach their full potential. Together, we can make a difference in their lives and contribute to a more inclusive, supportive world.

For more information about Project Matty, visit www.projectmatty.com. To schedule an interview or for more information, please contact Nora Lam at hello@projectmatty.com

Dr Pamela Lim Bio:

https://www.linkedin.com/in/dr-pamela-lim/?originalSubdomain=sg

PR Newswire

Medlinker’s MedGPT Performs 96% As Well As Top Human Doctors

Leave a comment

In a Livestreamed Real-World Assessment, MedGPT’s AI Doctors Rival Diagnostic Accuracy of China’s Leading Doctors

BEIJING, July 22, 2023 /PRNewswire/ — Medlinker, a leading digital healthcare company in China, undertook a real world comparison of AI doctors accessible through its MedGPT service and their human equivalents in Chengdu on June 30 2023.

The evaluation, streamed live, involved 120 real patients and ten attending physicians from West China Hospital, Sichuan University. Seven eminent physicians from leading Chinese hospitals reviewed and scored the results based on criteria including consultation accuracy, diagnosis, treatment recommendations, suggested additional examinations, data analysis, explanation provided to patients, and the use of natural language in patient interactions. Human doctors scored an average of 7.5 out of 10, while MedGPT scored 7.2. MedGPT’s recommendations were found to be 96% as good as those from top-tier physicians.

Launched by Medlinker on May 25 2023, MedGPT is China’s first homegrown medical large-scale language model founded on the Transformer architecture. Unlike general-purpose large-scale models, MedGPT was designed to provide practical diagnostic value in real medical scenarios, offering intelligent diagnosis and treatment capabilities throughout the entire process, from disease prevention to diagnosis, treatment, and rehabilitation. Medlinker’s ability to release a large-scale medical model ahead of its peers is the result of its accumulated expertise in artificial intelligence, big data, and internet-based healthcare. The world’s first real patient evaluation confirms Medlinker’s leadership in the research, development and application of medical large-scale language models.

The consultation session between doctor and patient was planned to fully ensure the impartiality and fact-based reliability of the evaluation, following a carefully established process:

  • The patient explained their medical situation, including symptoms and previous treatments, to the medical assistant;
  • The medical assistant relayed the collected information simultaneously to the human doctor and to MedGPT through online text input;
  • The medical assistant acted as the intermediary as doctor and patient completed multiple rounds of communication until sufficient information had been collected for a diagnosis;
  • Based on the information, the human doctor and MedGPT ordered specific follow-up examinations or, if the information provided was sufficient, provided a diagnosis to the patient;
  • If further examinations were required, the patient underwent examinations at the hospital;
  • After obtaining the examination results, the patient returned for a final consultation where MedGPT and the human doctor independently provided a clinical diagnosis and treatment.

Throughout the entire process, the human doctor and MedGPT worked independently with no sharing of information, to ensure that both were operating under the same conditions.

During the evaluation session, the medical experts on the panel were impressed by MedGPT’s performance. They generally agreed that MedGPT ensured medical accuracy by collecting sufficient information through multiple rounds of questioning, resulting in a relatively low probability of misdiagnosis or missed diagnosis. What was particularly surprising was that, unlike doctors specialized in one field, MedGPT could diagnose diseases outside its field of expertise and suggest a treatment program based on other clinical observations and factors, something that can be quite challenging to achieve in routine consultations undertaken by specialists. The panel concluded that MedGPT’s knowledge coverage surpassed that of human doctors with limited experience.

“The integration of AI doctors and telemedicine services is certain to disrupt the entire medical field,” said Wang Shirui, founder and CEO of Medlinker. “Looking into the future, we firmly believe that through Medlinker’s MedGPT, both the efficiency and the effectiveness of doctors will be vastly enhanced. At the same time, it will become possible to rapidly replicate high-quality medical resources and make them universally available. Furthermore, Medlinker’s telemedicine service network will be able to leverage MedGPT to provide more convenient, efficient and accessible medical services to a significantly larger pool of patients, vastly expanding medical inclusion, and taking a huge step towards solving the biggest dilemma facing the medical community today, providing medical services that are efficient and deliver meaningful treatment to the patient while remaining affordable.”

PR Newswire

Join Taipei City’s Thriving Health Industry: Registration for “Win A Greater Health” Pitch Contest Starts Now!

Leave a comment

TAIPEI, July 18, 2023 /PRNewswire/ — The Taipei City Government’s Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its “Talent Exchange Program”. In line with this initiative, they have established the “Taipei Entrepreneurs Hub (TEH)” to cultivate a vibrant international community of entrepreneurs in the heart of Taipei. In 2023, the spotlight is on the health industry, and the department is delighted to announce the forthcoming “Win A Greater Health” international online startup pitch contest. Registration is now open until September 15, 2023, Taipei time (UTC+8). International teams specializing in digital health fields are welcomed to participate.

The department places great importance on attracting international startup teams with key technologies and research capabilities to facilitate the cooperative transformation and upgrade of local industries. This has always been a crucial industrial goal for the city government. Additionally, harnessing the power of innovation and entrepreneurship to drive city diplomacy is a significant driving force. Therefore, in recent years, the department has actively connected global startup ecosystem resources through TEH, organizing various networking events across different industries and time zones, creating the most resource-rich and comprehensive entrepreneurial community. The ultimate goal is to welcome international entrepreneurs from around the world to establish their presence in Taipei.

This year, the international startup pitch contest, in collaboration with TEH, the Taiwan Digital Health Industry Development Association, BE Health Ventures, and the Taipei Medical University BioMed Accelerator, welcomes international startup teams to participate. The competition encourages teams to develop Taiwan market expansion plans with a focus on implementing their goals in Taipei City. The winning teams will not only receive one international round-trip ticket from anywhere to Taipei to attend the Demo Day presentation but also enjoy customized matchmaking sessions and business itineraries during their stay in Taipei. Selected teams will have diverse opportunities for technological connections, collaborations, and interactions with businesses and venture capital firms in Taipei.

In addition to organizing the competition, the city government has established StartUp@Taipei office and Inves Taipei office to support startups from around the world in settling in Taipei. The ultimate goal is to make Taipei City a partner for international talents and collaborate to develop more business opportunities.

For more information and registration details for the online competition, you can visit the official Facebook page or LinkedIn page, or contact the organizing company Everiii Consulting CO., Ltd. at (+886 2) 33435456 ext. 806, Ms. Kuo.

PR Newswire

Modernising Philanthropy: Kidney Dialysis Foundation Embraces Technology with over 50 GivePlease Donation Terminals Islandwide for Flag Day Fundraising

Leave a comment

Changing the fundraising landscape, one donation terminal at a time.  

SINGAPORE, July 14, 2023 /PRNewswire/ — The Kidney Dialysis Foundation (KDF) is set to revolutionise its annual Flag Day event on 15 July 2023 by introducing over 50 cutting-edge GivePlease donation terminals alongside traditional donation tins. This initiative demonstrates KDF’s commitment to embracing technology and providing a seamless, convenient, and secure donation experience for donors.

Figure 1: An example of a KDF GivePlease Donation Terminal that will be held by KDF staff and volunteers stationed islandwide on Flag Day. Photo courtesy of Kidney Dialysis Foundation.
Figure 1: An example of a KDF GivePlease Donation Terminal that will be held by KDF staff and volunteers stationed islandwide on Flag Day. Photo courtesy of Kidney Dialysis Foundation.

Flag Day holds immense significance for KDF, with volunteers and donors traditionally contributing through donation tins. While KDF recognises the enduring impact of these traditional methods, the foundation is taking a leap forward to meet the evolving preferences of donors, particularly the tech-savvy audience, by incorporating GivePlease donation terminals into the event. 

GivePlease donation terminals provide a modern and intuitive platform, designed specifically for donors who prefer seamless digital transactions. Developed with a built-in secure payment engine and innovative integration to GovTech Singpass, donors can effortlessly submit their particulars via Singpass QR code scanning and receive tax deduction benefits after giving to KDF. These state-of-the-art terminals will be strategically placed at various locations, making it easier than ever for individuals to contribute to KDF’s cause.

Mr. Raymond Lim, General Manager of the Kidney Dialysis Foundation, expressed his enthusiasm for the initiative, stating, “The introduction of GivePlease donation terminals during Flag Day signifies our unwavering commitment to innovation and exploring new avenues for fundraising.”

“This initiative reflects our commitment to embrace innovation and cater to the evolving preferences of our supporters. By blending technology with tradition, we are transforming the way people donate and ensuring that every contribution makes a meaningful difference in the lives of kidney patients,” he added.

With the adoption of GivePlease donation terminals, KDF aims to harness the power of technology and tap into the digital landscape to raise funds to help provide affordable and quality care for kidney patients. 

As Flag Day approaches, KDF invites individuals from all walks of life to participate in this remarkable event and contribute to the well-being of kidney patients in Singapore. Whether donors choose the convenience of the GivePlease donation terminals or the familiarity of the donation tins, every contribution counts and creates a significant impact on the lives of those affected by kidney disease.

The Flag Day event will be held on 15 July 2023, with a fundraising goal of $50,000 for needy kidney patients in Singapore. Funds raised will go into providing underprivileged kidney patients with treatments, medication, transport, and holistic care, as well as support the Foundation’s outreach efforts to increase awareness of kidney health. 

Members of the public can also contribute to this meaningful cause by visiting this link at
https://www.giving.sg/kidney-dialysis-foundation/kdffd23.

Appendix: GivePlease Donation Terminals

About Kidney Dialysis Foundation Singapore

Established in 1996, the Kidney Dialysis Foundation (KDF) is a company limited by guarantee. It is registered as a charity under the Charities Act 1994 and is governed and monitored by our Charity Sector Administrator, the Ministry of Health on behalf of the Commissioner of Charities. KDF is also an Institution of Public Character (IPC) charity organisation dedicated to providing subsidised dialysis treatments and holistic care to needy members of the community.

Kidney patients at KDF belong to the lowest 10% income group in Singapore, more than half of whom have a monthly per capita income (PCI) of $1,200 and below. Without subsidies, dialysis fees can set a patient back by more than $2,000 monthly. To date, KDF has served more than 950 patients, granting needy end-stage kidney patients a new lease of life through quality treatment and holistic care.

For more information about the Foundation, please visit https://www.kdf.org.sg/

About GivePlease

GivePlease is a leading Singapore-based fintech firm, at the forefront of seamless digital giving technology. With its ground-breaking on-demand donation platforms, GivePlease is transforming the experience of giving, combining digital and physical infrastructure to embed donation access points into people’s daily lives. By partnering with charities and religious organisations, GivePlease brings trust, transparency and a modernised donation experience that fosters increased generosity.

GivePlease builds technology for good and business for purpose. When donating is made easy and part of daily life, the world benefits and change is created. 

For more information, please visit www.giveplease.sg

For Media Enquiries,

Bellamy Leong (Mr.)
Donor Relations and Communications Executive
Kidney Dialysis Foundation
Tel: +65 98147598
Email: bellamy.leong@kdf.org.sg

Vincent Phua (Mr.)
Community and Partnerships Lead
GivePlease
Tel: +65 90406645        
Email: vincent.phua@giveplease.sg

PR Newswire

Lunit’s AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists’ Diagnostic Determination – Published in Radiology

Leave a comment

– Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists’ chest X-ray analysis performance

SEOUL, South Korea, July 3, 2023 /PRNewswire/ — Findings from a recent study demonstrate that medical AI solutions with only high diagnostic accuracy can significantly improve the reading performance of radiologists.

Lunit's chest X-ray AI analysis solution 'Lunit INSIGHT CXR'
Lunit’s chest X-ray AI analysis solution ‘Lunit INSIGHT CXR’

Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostics solutions, today announced the publication of a study exploring the impact of medical AI solutions’ accuracy on radiologists’ diagnostic determination. The study, conducted by Seoul National University Hospital from December 2015 to February 2021, was recently published in ‘Radiology,’ a renowned peer-reviewed journal in medical imaging.

The study involved a cohort of 30 doctors, including 20 board-certified radiologists with 5 to 18 years of expertise and 10 radiology residents with 2 to 3 years of training. A total of 120 retrospectively collected chest radiographs were assessed, with 60 obtained from patients with lung cancer and the remaining 60 showing no abnormalities.

During the first session, the 30 readers were divided into two groups and analyzed 120 chest X-rays each without the assistance of AI. In the subsequent session, each group reinterpreted the images with the aid of either a high-accuracy or low-accuracy AI model.

The high-accuracy AI model utilized in the study was Lunit INSIGHT CXR, Lunit’s commercially available AI solution for chest X-ray analysis. In contrast, the low-accuracy model was trained using only 10% of the data available to Lunit INSIGHT CXR. The AUROC (area under the receiver operating characteristic curve), a commonly used metric for diagnostic accuracy, of Lunit INSIGHT CXR was 0.88, while the low-accuracy AI model only reached 0.77.

The study revealed that using the higher-accuracy AI model, Lunit INSIGHT CXR, significantly improved radiologists’ performance. The AUROC was remarkably advanced from 0.77 to 0.82 when assisted by the high-accuracy AI model.

Conversely, the radiologists from the other group did not experience any performance improvement when utilizing the low-accuracy AI model, as the AUROC remained at 0.75. Moreover, the group that employed the high-accuracy AI model demonstrated a higher susceptibility to AI suggestions. The radiologists accepted 67% of AI recommendations that contradicted the initial reading results, compared to 59% acceptance of the group that utilized the low-accuracy AI model.

Moreover, the study findings highlighted that factors such as radiologists’ individual expertise, experience with AI, or attitudes toward AI had negligible impact on their reading performance in the second session. Instead, the accuracy of the AI model and the radiologists’ initial diagnostic accuracy emerged as the primary determinant shaping the final diagnostic determination.

These findings underscore the significance of the AI model’s performance when radiologists use AI as a second reader. Furthermore, the study demonstrates how such AI assistance can increase radiologists’ susceptibility to AI suggestions, ultimately contributing to more accurate diagnoses.

“The study backs that irrespective of radiologists’ individual characteristics, the utilization of high-performance AI significantly enhances diagnostic accuracy and fosters a greater acceptance of AI within medical practices,” said Brandon Suh, CEO of Lunit. “At Lunit, we are committed to developing AI-powered solutions that not only improve patient outcomes but also augment the expertise of healthcare professionals. This publication is a testament to our dedication to advancing the field of cancer diagnostics through cutting-edge technology.”

Radiology, owned and published by the Radiological Society of North America (RSNA), is a prestigious publication with a distinguished Impact Factor of 29.146, making it the number one ranked journal in the field of medical imaging.

About Lunit

Lunit is a deep learning-based medical AI company on a mission to conquer cancer, one of the leading causes of death worldwide. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit focuses on developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing giants like Google, IBM, and Microsoft. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship products, Lunit INSIGHT CXR and Lunit INSIGHT MMG, are clinically used in approximately 2,000 hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea with offices and representatives worldwide.

PR Newswire

United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI

Leave a comment

With uMI Panorama™, United Imaging Continues to Push the Envelope on Whole-Body System Performance

HOUSTON, June 26, 2023 /PRNewswire/ — United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year’s SNMMI, is making news on several fronts at SNMMI’s annual meeting in Chicago this week.

“There has been a debate in the marketplace for a while about the relative importance of resolution, axial field of view (FOV), and time of flight (TOF),” said Jeffrey Bundy, Ph.D, CEO of United Imaging Healthcare Solutions about the company’s product launch. “With the new wide-bore uMI Panorama and its 2.9 mm NEMA resolution, 35 cm axial FOV and 194 ps timing resolution, we will gladly have a conversation on any single specification or the collective benefit of all of them, because with this particular product, the need to compromise is gone.”

The uMI Panorama was teased recently in the media as one of United Imaging’s four new products in four different imaging modalities so far this year. Cheri Gottke, Vice President of the Molecular Imaging portfolio for the U.S., added that the uMI Panorama is currently installed at Huntsman Cancer Center in Salt Lake City, Utah and that “we chose SNMMI as the official stage to debut it.”   

United Imaging is showcasing a cutting-edge Molecular Imaging technology platform along with the uMI Panorama, called uExcel. The platform integrates hardware and software innovations to optimize performance, imaging capabilities and system functionalities. Its ultra-digital platform (UDP) detector boasts a high-performance ASIC chip, and its AI-empowered workflow streamlines operations and enhances examination efficiency. Exceptional image quality can be achieved with a lower dose, and the quality assurance module maintains peak performance of the system.

The uMI Panorama is a family of products that also includes a 510k pending system with a 148 cm axial FOV, the uMI Panorama GS. Built on the uExcel platform, this ultra-long axial FOV system allows for fast and high-resolution whole-body PET/CT imaging in a single bed position. The uMI Panorama GS is also being unveiled at SNMMI.  

United Imaging continues to see steady acceleration in demand for its popular digital PET/CT the uMI® 550, in both mobile and fixed configurations. “This is one of our most important molecular imaging innovations,” continued Gottke. “The entire digital portfolio from the uMI 550 to the uMI Panorama offers exceptional PET and CT image quality that improves quantitative accuracy and small lesion detectability. Our portfolio includes All-In Configurations™ and Software Upgrades for Life™ so that all our scanners truly stand the test of time from both a technological and a clinical perspective.”

The entire uMI portfolio is also “Born with AI” from the ground up, rather than being retrofitted with it later. This allows a seamless integration of artificial intelligence (AI) across all products, which optimizes daily workflow, improves the patient experience, and creates stunning diagnostic images. United Imaging’s artificial intelligence (uAI®) streamlines routine clinical workflows by auto iso-centering patients and defining the scan range. Its systems also allow faster scanning with less dose, while improving PET and CT imaging quality and providing image consistency in all clinical settings, from academic to freestanding imaging centers. 

SNMMI announced in its Value Initiative Newsletter that United Imaging is joining the Leadership Circle and taking an Industry co-chair position. 

United Imaging this week is also hosting two Satellite Symposiums (available for registration on the SNMMI meeting website) and a by-invitation-only customer event: 

uEXPLORER Symposium on June 25: “Exploring the Unmatched Capabilities of Total Body Imaging: Reflections on 5 Years of Clinical Adoption”; presenters include Dr. Ramsey Badawi, Vice Chair for Research, Department of Radiology, University of California, Davis and Dr. Harshad Kulkarni, Chief Medical Advisor, BAMF Health.

uMI Panorama Symposium on June 26: “Advancing Precision Medicine with Unprecedented PET/CT Technology for Clinical Molecular Imaging” on Monday, June 26, from 11:30 am – 12:30 pm. Presenters include Dr. Jeffrey Yap, Director, Center for Quantitative Imaging at Huntsman Cancer Institute.

United Imaging Educational Evening “UIH Night” (Invitation Only), Sunday June 25th. Presenters include Dr. Richard Carson, Professor of Biomedical Engineering and Radiology, Yale University and Dr. Simon Cherry, Professor of Biomedical Engineering and Radiology, UC Davis

United Imaging is located at booth #4032.

ABOUT UNITED IMAGING
At United Imaging, we develop and manufacture advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change.

To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC.

Source: United Imaging Healthcare Co., Ltd.

PR Newswire

Waterdrop Inc. Announces Earnings Date Change: First Quarter 2023 Earnings Release Scheduled June 2, 2023

Leave a comment

BEIJING, May 31, 2023 /PRNewswire/ — Waterdrop Inc. (NYSE: WDH) (“Waterdrop” or the “Company”), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2023, before U.S. markets open on Friday, June 2, 2023, instead of the previously announced date of June 5, 2023.

Waterdrop’s management team will hold a conference call on June 2, 2023 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Chinese Line (Mandarin) Entry Number:

6683992

English Interpretation Line (Listen-only Mode) Entry Number:

8700524

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

Telephone replays will be accessible two hours after the conclusion of the conference call through June 9, 2023 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Chinese Line Access Code:

1702325

English Interpretation Line Access Code:

8201572

Additionally, live and archived webcasts of the conference call will be available at the Company’s investor relations website at http://ir.waterdrop-inc.com/.

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

For investor inquiries, please contact

Waterdrop Inc.
IR@shuidi-inc.com

Source: Waterdrop Inc.

PR Newswire

Frost & Sullivan Institute Announces the Launch of the 2023 Enlightened Growth Leadership Awards for Emerging Companies to Recognize Companies Driving a Sustainable Future

Leave a comment

SANTA CLARA, Calif., May 3, 2023 /PRNewswire/ — Frost & Sullivan Institute, in partnership with Frost & Sullivan announces the launch of the Enlightened Growth Leadership Awards, 2023 – Emerging Companies* edition. The award recognizes emerging companies that drive transformation toward a sustainable future.

Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023
Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023

“The winning companies represent a diverse range of industries and geographies. However, they all share a deep commitment towards innovating global challenges to zero and a drive to create a positive impact through their products, services and business strategies,” said David Frigstad, Director, Frost & Sullivan Institute.

In order to identify companies that are setting the standard for sustainability, we use a rigorous eight-step methodology coupled with thought leadership and global think tanks. The company’s products and services are designed to address global challenges to zero in addition to achieving Growth Excellence. In honoring and celebrating companies that are promoting sustainable practices, we hope to inspire others to join this movement.

Frost & Sullivan Institute congratulates all the recipients of the Enlightened Growth Leadership Awards for Emerging Companies, 2023. We will recognize and celebrate the 2023 emerging company award recipients at our Virtual Awards Ceremony in June.

*For the purpose of this award, we define Emerging Companies as companies that are 3-5 years in the market and have products/services focused on innovating global challenges to zero.

Recipients:

Alto

Ancala Water Services

Anduril

Armo Security

AUM Biosciences

Aura

Autokiniton Global Group

Axonius

BP Bunge Bioenergia

Calm (Therapeutic Devices)

Campus Energy Partners

Central Rivers Power

CentralSquare Technologies

Cityblock

Coalition

CommonSpirit Health

Converged Security Solutions

CyCraft Technologies

CYSEC

Easee (Electronics)

About Frost & Sullivan Institute

The Frost & Sullivan Institute (FSI) is a non-profit organization dedicated to utilizing business practices to address global priorities. The genesis of the institute goes back to the vision of either creating, or becoming part of, a solution that addresses threats to humanity. The Institute has identified strategic imperatives for transformation and believes that we can truly accelerate innovation to zero. To learn more about FSI, visit www.frostandsullivaninstitute.org

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Media Contact:

Prerna Mohan
Email: prerna.mohan@frost.com

SOURCE Frost & Sullivan

Related Links
www.frost.com 
www.frostandsullivaninstitute.org